MHMasaki Hatano

Masaki Hatano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masaki Hatano has a total of 63 co-authors. Here are the top co-authors by number of shared publications:

  • Hideo Yasunaga

    Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo

    15 shared publications
  • Takeyuki Tanaka

    Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo

    15 shared publications
  • Hisatoshi Ishikura

    Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo

    13 shared publications
  • Sakae Tanaka

    Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo

    11 shared publications
  • Izuru Kitajima

    Department of Orthopaedic Surgery, Toranomon Hospital, Kawasaki, Kanagawa Prefecture, Japan

    10 shared publications
  • Seizo Yamamoto

    Department of Orthopaedic Surgery, Toranomon Hospital, Kawasaki, Kanagawa Prefecture, Japan

    10 shared publications

Latest Publications

  • Open Access

    Pharmacological management of knee and hip osteoarthritis stratified by oral nonsteroidal anti-inflammatory drugs safety status

    by Masaki Hatano, Yuya Kimura, Akira Okada, Hisatoshi Ishikura, Takeyuki Tanaka, Sakae Tanaka, Hideo Yasunaga

    Introduction: Knee and hip osteoarthritis are treated with oral nonsteroidal anti-inflammatory drugs (NSAIDs); however, pharmacological management by NSAID safety status remains unclear. We characterized pharmacological treatment patterns across safety strata. Materials and methods: We used Japanese health insurance claims database (2014–2024). Adults aged ≥40 years with incident knee or hip osteoarthritis were classified as having oral NSAID contraindications, precautions, or neither. Outcomes were receipt of oral NSAIDs within 90 days of osteoarthritis diagnosis. Adjusted risk differences (RDs) were estimated with identity-link binomial models and facility-clustered standard errors. Results: For knee osteoarthritis, oral NSAIDs were prescribed to 49.0%, 44.0%, and 30.2% of patients in the no contraindications or precautions, precaution, and contraindication groups, respectively, and to 53.4%, 48.6%, and 34.5% of patients with hip osteoarthritis. Compared with patients with no contraindications or precautions, the adjusted RDs for receiving oral NSAIDs were −2.0 (95% confidence interval [CI], −2.6 to −1.4) and −12.9 (95% CI −14.1 to −11.7) for knee osteoarthritis, and −1.9 (95% CI −3.3 to −0.5) and −13.0 (95% CI −15.7 to −10.3) for hip osteoarthritis, for the precaution and contraindication groups, respectively. Adjusted RDs for receiving non-NSAID treatments were 0.5 (95% CI −0.1 to 1.1) and −2.0 (95% CI −3.4 to −0.6) for knee osteoarthritis, and 1.1 (95% CI −0.2 to 2.3) and 3.1 (95% CI 0.3 to 5.8) for hip osteoarthritis, respectively. Conclusion: Oral NSAID use was less frequent among patients classified as having oral NSAID precautions or contraindications than among those without such classifications in both cohorts.

  • Open Access

    Osteoarthritis risk associated with denosumab in adults with osteoporosis: a target trial emulation

    by Masaki Hatano, Yuya Kimura, Akira Okada, Hisatoshi Ishikura, Takeyuki Tanaka, Taku Saito, Sakae Tanaka, Hideo Yasunaga

    Denosumab, a well-established osteoporosis treatment, has demonstrated potential bone- and cartilage-protective effects in preclinical and early trials. However, it remains unclear whether these promising findings extend to osteoarthritis prevention in weight-bearing joints and broader real-world osteoporotic populations. We compared osteoarthritis incidence between denosumab and oral bisphosphonates in adults aged 50 yr or older with osteoporosis using a sequential nested target trial emulation with propensity score matching based on longitudinal health insurance claims data from Japan collected between 2015 and 2024. Two target comparisons were conducted: one compared new users of denosumab with new users of oral bisphosphonates, and the other compared patients who switched from oral bisphosphonates to denosumab with those who continued oral bisphosphonates. The primary outcome was osteoarthritis incidence. Secondary outcomes included joint-specific osteoarthritis (knee, hip, and hand) over 3 yr. The absolute risk reduction (ARR) and relative risk (RR) at 3 yr were estimated using a Kaplan–Meier estimator in both the per-protocol and intention-to-treat (ITT) analyses. In the per-protocol analyses, the ARR for incident osteoarthritis was 2.0% (95% CI, 1.1%-3.2%) in the new-user comparison, with an RR of 0.83 (95% CI, 0.73-0.91), and 0.9% (95% CI, −0.2% to 2.8%) in the switch-continue comparison, with an RR of 0.92 (95% CI, 0.76-1.02). In the ITT analyses, the corresponding ARR was 1.9% (95% CI, 1.3%-3.3%) in the new-user comparison, with an RR of 0.84 (95% CI, 0.73-0.89), and 1.2% (95% CI, −0.2% to 2.7%) in the switch-continue comparison, with an RR of 0.89 (95% CI, 0.77-1.02). Denosumab initiation was associated with a modestly lower risk of incident osteoarthritis than oral bisphosphonate initiation, although the association was weaker in the switch-continue comparison.

  • Open Access

    Cefazolin Dose–Response-based Correlation of Weight With Orthopaedic Implant-related Surgical-site Infections

    by Masaki Hatano, Yusuke Sasabuchi, Koji Yamada, Shotaro Aso, Hisatoshi Ishikura, Takeyuki Tanaka, Sakae Tanaka, Hideo Yasunaga

    Background: This study aimed to evaluate the association of the initial body weight-stratified cefazolin antimicrobial prophylaxis (AMP) dose and surgical-site infection (SSI) in major orthopedic implant surgery.Methods: This nationwide, retrospective cohort study used data from the Diagnosis Procedure Combination database. We included patients (age ≥18 years) who underwent major orthopedic implant surgery between July 2010 and March 2022. Patients underwent surgery with an initial cefazolin dose of either 1 g (1 g cefazolin group) or 2 g (2 g cefazolin group). Primary outcome was in-hospital SSI. Restricted cubic spline functions were used to estimate the nonlinear association of body weight-stratified cefazolin dose with the outcome and between cefazolin dose per weight and the outcome.Results: Among the 408,487 participants, 394,731 and 13,756 were in the 1 g and 2g cefazolin groups, respectively. The 1 g cefazolin group, but not the 2 g cefazolin group, showed a J-shaped relationship between body weight and SSI, which increased continuously beyond 50 kg, in an increased risk of SSI with body weight. A reverse J-shaped relationship was observed between cefazolin dose per weight and SSI, with an increased risk of SSI at 50 kg.

  • Open Access

    Trends in anti-osteoporosis pharmacotherapy and pharmacological initiation for secondary fracture prevention in Japan, 2017–2023

    by Masaki Hatano, Akira Okada, Yuya Kimura, Hisatoshi Ishikura, Takeyuki Tanaka, Taku Saito, Sakae Tanaka, Hideo Yasunaga

  • Open Access

    Improving the design of observational studies in orthopaedics: a practical guide to target trial emulation

    by Masaki Hatano, Yuya Kimura, Hideo Yasunaga, Sakae Tanaka

    Purpose: To explain how target trial emulation can help orthopaedic researchers design observational studies that are more clinically interpretable and less vulnerable to avoidable design bias. Methods: We provide a methodological overview of target trial emulation for orthopaedic research, using the comparison of postoperative outcomes after total hip arthroplasty versus bipolar hemiarthroplasty for hip fracture as an illustrative example. The review focused on translating a causal question into a target trial protocol, how conventional observational designs can introduce bias, and how routinely collected data can be used to emulate a target trial when key design conditions are met. Results: Target trial emulation begins by specifying the clinical question, hypothetical trial, and assumptions required for causal interpretation. This explicit specification is particularly relevant to orthopaedic observational research, wherein treatment decisions are often influenced by prognosis, functional status, surgeon judgment, and institutional context. Conventional observational analyses may be difficult to interpret when the eligibility criteria include patients for whom one treatment is not realistic, treatment labels combine important procedural variations, treatment assignment and follow-up are not aligned at time zero, or post-baseline information is used to modify follow-up or exclude patients. This framework can emphasise these problems before analysis, although it cannot overcome residual confounding, poor measurement, informative loss to follow-up, or other data limitations. Conclusions: Target trial emulation can guide observational studies’ design around treatment decisions encountered in routine practice. Its application may help orthopaedic researchers produce studies that are more transparent, clinically interpretable, and better aligned with decision-making in practice.


  • Corrigendum to Osteoarthritis risk associated with romosozumab compared with teriparatide in individuals with osteoporosis: A target trial emulation study Ann Rheum Dis 2025;84(11):1938-1947

    by Masaki Hatano, Yusuke Sasabuchi, Akira Okada, Yuya Kimura, Hisatoshi Ishikura, Takeyuki Tanaka, Taku Saito, Sakae Tanaka, Hideo Yasunaga

  • Open Access

    Impact of a national reimbursement add-on policy on refracture risk and secondary fracture prevention after hip fracture in Japan: a population-based interrupted time series analysis

    by Masaki Hatano, Taku Saito, Yuya Kimura, Hisatoshi Ishikura, Takeyuki Tanaka, Hideo Yasunaga, Sakae Tanaka

    In Japan, a national reimbursement add-on for secondary fracture prevention after hip fracture surgery, implemented on April 1, 2022, was associated with lower 1-year refracture risk and higher early uptake of post-fracture DXA assessment within 90 days and anti-osteoporosis medication initiation within 120 days, but not with improved 1-year post-fracture treatment persistence. To assess whether the Japanese national reimbursement add-on policy for preventing secondary fracture after hip fracture surgery, introduced in April 2022, was associated with actual changes in refracture risk and key secondary fracture prevention care processes after hip fracture surgery. We conducted a population-based interrupted time-series analysis using longitudinal health insurance claims data collected in Japan between 2019 and 2023. Participants were adults aged ≥ 50 years with newly identified and surgically treated hip fracture. The intervention was implementation of the policy on 1 April 2022. Outcome measures were absolute changes 12 months after policy implementation in the 1-year cumulative risk of first refracture, 90-day cumulative probability of receiving dual-energy X-ray absorptiometry (DXA) assessment, 120-day cumulative probability of initiating anti-osteoporosis medication, and 1-year post-fracture treatment persistence. Twelve months after policy implementation, the absolute effect on the 1-year cumulative risk of refracture in the hip fracture series was - 1.02 percentage points (95% confidence interval, - 1.44 to - 0.60). The absolute effects on early care processes were 41.37 percentage points (40.21 to 42.54) for DXA assessment and 22.83 percentage points (21.70 to 23.95) for the initiation of anti-osteoporosis medication. The absolute effect on 1-year post-fracture treatment persistence was - 6.76 percentage points (- 10.04 to - 3.49). The reimbursement add-on policy for secondary fracture prevention after hip fracture surgery was associated with a lower 1-year cumulative refracture risk and a higher cumulative probability of receiving DXA assessment and initiating anti-osteoporosis medication, but not with improved 1-year post-fracture treatment persistence. Strategies supporting sustained follow-up and reengagement may be needed.


  • Open Access

    Romosozumab versus teriparatide for risk of dementia in individuals with osteoporosis: a target trial emulation study

    by Masaki Hatano, Akira Okada, Yusuke Sasabuchi, Yuya Kimura, So Sato, Hisatoshi Ishikura, Takeyuki Tanaka, Taku Saito, Sakae Tanaka, Hideo Yasunaga

    This target-trial emulation study sought to assess the association between romosozumab and incident dementia. We analyzed longitudinal claims data from 69,543 Japanese individuals with osteoporosis (using teriparatide as an active comparator), finding that romosozumab initiation among individuals with osteoporosis may correlate with a lower dementia risk than teriparatide initiation. The neurocognitive benefits of osteoporosis treatments remain underexplored despite growing interest in the bone-brain connection. We aimed to analyze the association between romosozumab and incident dementia, using teriparatide as the active comparator. We emulated a target trial using longitudinal commercial claims data from Japan. We identified individuals aged ≥ 50 years with osteoporosis who newly initiated either romosozumab or teriparatide between 2019 and 2023. The primary outcome was incident dementia, and the secondary outcome was Alzheimer's disease. We estimated the absolute risk reduction (ARR) and relative risk (RR) using a weighted Kaplan-Meier estimator, conducting both intention-to-treat and per-protocol analyses. A total of 69,543 individuals were included in the study (90% female; mean age, 81 years). In the 2-year intention-to-treat analyses, the ARR was 0.7% (95% confidence interval, - 0.1 to 1.3%), with a RR of 0.91 (95% confidence interval, 0.84 to 1.01). For Alzheimer's disease specifically, the ARR was 0.6% (95% confidence interval, 0.0 to 1.1%), with an RR of 0.88 (95% confidence interval, 0.79 to 1.00). In the 1-year per-protocol analyses, the ARR was 1.0% (95% confidence interval, 0.7 to 1.4%), with a RR of 0.76 (95% confidence interval, 0.69 to 0.82). For Alzheimer's disease specifically, the ARR was 0.6% (95% confidence interval, 0.3 to 0.9%), with an RR of 0.77 (95% confidence interval, 0.65 to 0.86). In this target trial emulation study, romosozumab initiation among individuals with osteoporosis may be associated with a lower risk of dementia, particularly Alzheimer's disease, than teriparatide initiation.

  • Open Access

    Oral bisphosphonates and risk of incident osteoarthritis in individuals with osteoporosis: a target trial emulation

    by Masaki Hatano, Yuya Kimura, Akira Okada, Hisatoshi Ishikura, Takeyuki Tanaka, Taku Saito, Sakae Tanaka, Hideo Yasunaga

    Objectives: Owing to the underrepresentation of early-stage disease in randomised trials and inconsistent clinical evidence, using oral bisphosphonates to prevent incident osteoarthritis in adults with osteoporosis lacks consensus. We aimed to analyse the causal relationship between oral bisphosphonates and osteoarthritis. Methods: We performed a sequential nested target trial emulation with propensity score matching using longitudinal health insurance claims data from Japan collected between 2015 and 2024. Eligible individuals were aged ≥50 years with osteoporosis who had been receiving vitamin D therapy. We compared those who initiated oral bisphosphonates with those who did not initiate and continued vitamin D therapy. The primary outcome was incident osteoarthritis. Secondary outcomes included joint-specific osteoarthritis (knee, hip and hand) over a 3-year follow-up period. The absolute risk reduction (ARR) and relative risk (RR) at 3 years were estimated using a Kaplan-Meier estimator. Results: We included 10 844 bisphosphonate initiators and 21 283 non-initiators. The ARR for incident osteoarthritis was 0.4% (95% CI –1.3% to 1.0%), with an RR of 0.97 (95% CI 0.92 to 1.12). In joint-specific analyses, the ARR (95% CI) and RR (95% CI) were 0.5% (–1.1% to 1.0%) and 0.95 (0.90 to 1.12) for knee osteoarthritis; 0.2% (–0.4% to 0.7%) and 0.89 (0.64 to 1.27) for hip osteoarthritis; and –0.3% (–0.7% to 0.3%) and 1.20 (0.81 to 1.50) for hand osteoarthritis, respectively. Conclusion: Oral bisphosphonate use was not associated with a lower risk of incident osteoarthritis among adults with osteoporosis.


  • Advantages of cemented stems in facilitating early postoperative rehabilitation after total hip arthroplasty: a propensity score-matched analysis

    by Hisatoshi Ishikura, Toru Nishiwaki, Yuji Masuyama, Sho Fujita, Masaki Hatano, Takeyuki Tanaka, Sakae Tanaka

    Purpose: This study examined whether cemented stems in total hip arthroplasty (THA) accelerate postoperative rehabilitation compared to cementless stems, even in patients with osteoporosis. Methods: A retrospective analysis of 232 unilateral THAs included cemented ( n = 84) and cementless ( n = 148) groups. Propensity score matching yielded 53 matched pairs. Outcomes included rehabilitation milestones (initiation of T-cane walking, stable ambulation, and stair climbing), length of hospital stay, and clinical scores. Perioperative parameters, such as operative time, blood loss, and pain scores were also assessed. Results: The cemented group achieved earlier initiation (4.2 ± 2.4 vs. 5.2 ± 2.6 days, respectively; p < 0.05) and stabilisation (5.3 ± 3.1 vs. 6.6 ± 3.4 days, p < 0.05) of T-cane walking compared to the cementless group. No significant differences were observed in stair-climbing time or length of hospital stay. Despite greater intraoperative blood loss in the cemented group, the estimated total and postoperative blood losses were comparable. Both groups showed similar improvements in clinical scores over 12 months. Conclusions: Cemented stems facilitated earlier ambulation without compromising long-term outcomes, supporting their use in osteoporotic patients for early postoperative recovery.